ANRS CO21 Cohort

{
"level_sex_clusion_I": [
{
"value": "Male",
"concept": {
"vocab": "MeSH",
"vocabURI": "http:\/\/id.nlm.nih.gov\/mesh\/D008297"
}
},
{
"value": "Female",
"concept": {
"vocab": "MeSH",
"vocabURI": "http:\/\/id.nlm.nih.gov\/mesh\/D005260"
}
},
{
"value": "Other",
"concept": {
"vocab": [],
"vocabURI": []
}
}
],
"level_age_clusion_I": [
{
"value": "Young Adult (19 to 24 years)",
"concept": {
"vocab": "MeSH",
"vocabURI": "http:\/\/id.nlm.nih.gov\/mesh\/D055815"
}
},
{
"value": "Adult (25 to 44 years)",
"concept": {
"vocab": "MeSH",
"vocabURI": "http:\/\/id.nlm.nih.gov\/mesh\/D000328"
}
},
{
"value": "Middle Aged (45 to 64 years)",
"concept": {
"vocab": "MeSH",
"vocabURI": "http:\/\/id.nlm.nih.gov\/mesh\/D008875"
}
},
{
"value": "Aged (65 to 79 years)",
"concept": {
"vocab": "MeSH",
"vocabURI": "http:\/\/id.nlm.nih.gov\/mesh\/D000368"
}
}
],
"level_type_clusion_I": [
"Patients population"
],
"level_type_clusion_other": "",
"clusion_I": "LTNP subjects: Long Term Non Progressors: HIV-1 positive subjects for at least 8 years with a CD4+ lymphocyte count greater than 600\/mm3 and stable or increasing (positive or zero slope) on at least 3 consecutive tests performed in the last 5 years regardless of viral load in the absence of antiretroviral treatment. HIC (HIV Controllers)\" subjects: HIV-1 positive subjects for at least 5 years, asymptomatic, with the last 5 consecutive plasma HIV RNA viral loads < 400 copies\/mL whatever the CD4+ level in the absence of antiretroviral treatment. LTNP-HIC\" subjects: subjects meeting the double definition of LTNP and HIC, i.e. HIV-1 subjects who have been HIV-positive for at least 8 years and CD4+ lymphocyte count greater than 600\/mm3 with a stable or increasing level (positive or zero slope) on at least 3 consecutive examinations carried out over the last 5 years and with the last 5 consecutive plasma HIV-RNA viral loads < 400 copies\/mL. Subjects in \"post-treatment control\" (or post-treatment controllers, PTC): Subjects who had a plasma HIV-RNA viral load > 2000 copies\/mL prior to initiation of antiretroviral therapy in either primary or chronic phase and who were maintained on antiretroviral therapy for at least 12 months; in whom, after antiretroviral therapy was discontinued, the viral load remained < 400 copies\/mL for more than 12 months with the exception of one blip (plasma viral load above 400 copies\/mL) surrounded by two viral loads < 400 copies\/mL. The last plasma viral load at the time of inclusion should, in all cases, be < 400 copies\/mL.",
"clusion_E": ""
}